{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:36Z","timestamp":1790361696542,"version":"4.1.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"John Patrick Carey Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Mesenchymal stromal cells (MSCs) can modulate immune responses and suppress inflammation in autoimmune diseases. Although their safety has been established in clinical trials, the efficacy of MSCs is inconsistent due to variability in potency among different preparations and limited specificity in targeting mechanisms driving autoimmune diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We utilized high-dimensional design of experiments methodology to identify factor combinations that modulate gene expression by MSCs to mitigate inflammation. This led to a novel MSC-based cell therapy, HXB-319. Its anti-inflammatory properties were validated in vitro by flow cytometry, RT-PCR, and mass spectrophotometry. To evaluate in vivo efficacy, we treated a diffuse alveolar hemorrhage (DAH) mouse model (C57Bl\/6). Seven days post-DAH induction with pristane, mice received either MSCs or HXB-319 (2X106 cells, IP). On day 14, peritoneal lavage fluid (PLF) and lung tissue were collected for flow cytometry, histopathological examination, and mRNA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HXB-319 increased gene expression levels of anti-inflammatory, angiogenic, and anti-fibrotic factors (eg, TSG-6, VEGF, and HGF). KEGG pathway analysis confirmed significant activation of relevant anti-inflammatory, angiogenic, and anti-fibrotic proteins, corroborating RT-PCR results. In the DAH model, HXB-319 significantly reduced lung inflammation and alveolar hemorrhage compared to MSC-treated and untreated DAH mice. HXB-319 treatment also significantly decreased neutrophils, plasmacytoid dendritic cells, and ROR\u03b3T cells, increased FoxP3+ cells in PLF, and reversed alterations in mRNA encoding IL-6, IL-10, and TSG-6 in lung tissue compared to DAH mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HXB-319 effectively controls inflammation and prevents tissue damage in pristine-induced DAH, highlighting its therapeutic potential for autoimmune inflammatory diseases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/stmcls\/sxae078","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:45:23Z","timestamp":1732016723000},"source":"Crossref","is-referenced-by-count":4,"title":["Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-9068","authenticated-orcid":false,"given":"Hulya","family":"Bukulmez","sequence":"first","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Metrohealth Medical Center, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne T","family":"Dennis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Metrohealth Medical Center, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Reese-Koc","sequence":"additional","affiliation":[{"name":"Cellular Therapy Operations and Quality, National Center for Regenerative Medicine, School of Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F","family":"Sieg","sequence":"additional","affiliation":[{"name":"Immunology Flow Core, Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clagett","sequence":"additional","affiliation":[{"name":"Immunology Flow Core, Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kleinsorge-Block","sequence":"additional","affiliation":[{"name":"Cellular Therapy Operations and Quality, National Center for Regenerative Medicine, School of Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Somoza-Palacios","sequence":"additional","affiliation":[{"name":"Skeletal Research Center, Department of Biology, College of Arts and Sciences, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Singer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Metrohealth Medical Center, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chance","sequence":"additional","affiliation":[{"name":"Center for Proteomics and Bioinformatics, School of Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin B","family":"Highland","sequence":"additional","affiliation":[{"name":"Department of Pulmonary\/Critical Care, Rheumatic Lung Disease Program, Cleveland Clinic Foundation, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven N","family":"Emancipator","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Case Western Reserve University , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"2025031206132002300_CIT0001","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1055\/s-0031-1279823","article-title":"Lung vasculitis and alveolar hemorrhage: pathology","volume":"32","author":"Fishbein","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"2025031206132002300_CIT0002","doi-asserted-by":"publisher","first-page":"000687","DOI":"10.12890\/2017_000687","article-title":"Goodpasture\u2019s syndrome with negative anti-glomerular basement membrane antibodies","volume":"4","author":"Vries","year":"2017","journal-title":"Eur J Case Rep Intern Med"},{"key":"2025031206132002300_CIT0003","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13054-020-02936-0","article-title":"Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study","volume":"24","author":"Mirouse","year":"2020","journal-title":"Crit Care"},{"key":"2025031206132002300_CIT0004","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12890-020-01181-z","article-title":"Clinical implication of plasma exchange on life-threatening antineutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Park","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2025031206132002300_CIT0005","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/labinvest.2011.108","article-title":"Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane","volume":"91","author":"Barker","year":"2011","journal-title":"Lab Invest"},{"key":"2025031206132002300_CIT0006","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaut.2019.03.009","article-title":"Neutrophil extracellular traps are associated with the pathogenesis of diffuse alveolar hemorrhage in murine lupus","volume":"100","author":"Jarrot","year":"2019","journal-title":"J Autoimmun"},{"key":"2025031206132002300_CIT0007","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/jcm8091341","article-title":"Alpha-1-antitrypsin ameliorates pristane induced diffuse alveolar hemorrhage in mice","volume":"8","author":"Elshikha","year":"2019","journal-title":"J Clin Med"},{"key":"2025031206132002300_CIT0008","doi-asserted-by":"publisher","first-page":"633212","DOI":"10.3389\/fcvm.2021.633212","article-title":"PEGylated Serp-1 markedly reduces pristane-induced experimental diffuse alveolar hemorrhage, altering uPAR distribution, and macrophage invasion","volume":"8","author":"Guo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025031206132002300_CIT0009","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-0716-1012-1_14","article-title":"Preclinical testing of viral therapeutic efficacy in pristane-induced lupus nephritis and diffuse alveolar hemorrhage mouse models","volume":"2225","author":"Guo","year":"2021","journal-title":"Methods Mol Biol"},{"key":"2025031206132002300_CIT0010","doi-asserted-by":"publisher","first-page":"e129703","DOI":"10.1172\/jci.insight.129703","article-title":"High-dimensional analysis reveals a pathogenic role of inflammatory monocytes in experimental diffuse alveolar hemorrhage","volume":"4","author":"Lee","year":"2019","journal-title":"JCI Insight"},{"key":"2025031206132002300_CIT0011","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.4049\/jimmunol.1901312","article-title":"Erythropoietin protects against diffuse alveolar hemorrhage in mice by regulating macrophage polarization through the EPOR\/JAK2\/STAT3 axis","volume":"206","author":"Yang","year":"2021","journal-title":"J Immunol"},{"key":"2025031206132002300_CIT0012","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s10067-017-3811-6","article-title":"Pristane-induced lupus: considerations on this experimental model","volume":"36","author":"Freitas","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025031206132002300_CIT0013","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1517\/14712591003769816","article-title":"Allogenic bone-marrow-derived mesenchymal stem cells transplantation as a novel therapy for systemic lupus erythematosus","volume":"10","author":"Zhang","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"2025031206132002300_CIT0014","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00005-021-00603-y","article-title":"Functional characteristics and application of mesenchymal stem cells in systemic lupus erythematosus","volume":"69","author":"Tang","year":"2021","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2025031206132002300_CIT0015","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.imlet.2015.05.017","article-title":"Mesenchymal stromal cells and rheumatic disorders","volume":"168","author":"Tyndall","year":"2015","journal-title":"Immunol Lett"},{"key":"2025031206132002300_CIT0016","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/ard.2010.132639","article-title":"Mesenchymal stem cells in the treatment of autoimmune diseases","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025031206132002300_CIT0017","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/bmt.2009.63","article-title":"Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks","volume":"43","author":"Tyndall","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2025031206132002300_CIT0018","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11926-008-0032-7","article-title":"Cellular therapy of systemic sclerosis","volume":"10","author":"van Laar","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"2025031206132002300_CIT0019","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/cells9071660","article-title":"Mechanisms behind the immunoregulatory dialogue between mesenchymal stem cells and Th17 cells","volume":"9","author":"Terraza-Aguirre","year":"2020","journal-title":"Cells"},{"key":"2025031206132002300_CIT0020","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/sctm.17-0002","article-title":"Serum IFN-gamma predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients","volume":"6","author":"Wang","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"2025031206132002300_CIT0021","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2474-13-249","article-title":"The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system","volume":"13","author":"Wang","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"2025031206132002300_CIT0022","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/cmi.2015.89","article-title":"The regulation of the Treg\/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus","volume":"14","author":"Wang","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"2025031206132002300_CIT0023","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0961203308100385","article-title":"Cellular therapy of systemic lupus erythematosus","volume":"18","author":"Tyndall","year":"2009","journal-title":"Lupus"},{"key":"2025031206132002300_CIT0024","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41422-021-00573-y","article-title":"Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms","volume":"31","author":"Zhu","year":"2021","journal-title":"Cell Res"},{"key":"2025031206132002300_CIT0025","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s12015-012-9364-9","article-title":"IL1beta induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-kappaB","volume":"8","author":"Carrero","year":"2012","journal-title":"Stem Cell Rev Rep"},{"key":"2025031206132002300_CIT0026","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s13287-019-1449-9","article-title":"Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease-a gut feeling","volume":"10","author":"Gavin","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"2025031206132002300_CIT0027","doi-asserted-by":"publisher","first-page":"1136614","DOI":"10.3389\/fphar.2023.1136614","article-title":"Mesenchymal stem cells elicits anti-PD1 immunotherapy by targeted delivery of CX3CL1","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025031206132002300_CIT0028","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/stem.3380","article-title":"Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity","volume":"39","author":"Galipeau","year":"2021","journal-title":"Stem Cells"},{"key":"2025031206132002300_CIT0029","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12969-021-00575-5","article-title":"Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series","volume":"19","author":"Wong","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025031206132002300_CIT0030","doi-asserted-by":"publisher","first-page":"643170","DOI":"10.3389\/fimmu.2021.643170","article-title":"Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors","volume":"12","author":"El-Jawhari","year":"2021","journal-title":"Front Immunol"},{"key":"2025031206132002300_CIT0031","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ecco-jcc\/jjac172","article-title":"A phase IB\/IIA study of allogeneic, bone marrow-derived, mesenchymal stem cells for the treatment of refractory ileal-anal anastomosis and peripouch fistulas in the setting of Crohn\u2019s disease of the pouch","volume":"17","author":"Lightner","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025031206132002300_CIT0032","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13287-020-02087-7","article-title":"The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-gamma and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase","volume":"12","author":"Lim","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2025031206132002300_CIT0033","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3389\/fimmu.2018.02013","article-title":"Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges","volume":"9","author":"Peltzer","year":"2018","journal-title":"Front Immunol"},{"key":"2025031206132002300_CIT0034","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/0961203320928419","article-title":"Immunotherapeutic effects of allogeneic mesenchymal stem cells on systemic lupus erythematosus","volume":"29","author":"Liu","year":"2020","journal-title":"Lupus"},{"key":"2025031206132002300_CIT0035","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1002\/art.27560","article-title":"Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus","volume":"62","author":"Schena","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025031206132002300_CIT0036","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00109-019-01776-y","article-title":"Current understanding of the immunosuppressive properties of mesenchymal stromal cells","volume":"97","author":"de Castro","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"2025031206132002300_CIT0037","doi-asserted-by":"publisher","first-page":"104133","DOI":"10.1016\/j.isci.2022.104133","article-title":"Controlling neural territory patterning from pluripotency using a systems developmental biology approach","volume":"25","author":"Sears","year":"2022","journal-title":"iScience"},{"key":"2025031206132002300_CIT0038","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1530\/ERC-19-0042","article-title":"Therapeutic strategies to induce ERalpha in luminal breast cancer to enhance tamoxifen efficacy","volume":"26","author":"Esakov","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2025031206132002300_CIT0039","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/ph16020220","article-title":"Human Mesenchymal Stem Cell (hMSC) donor potency selection for the \u201cfirst in cystic fibrosis\u201d phase I clinical trial (CEASE-CF)","volume":"16","author":"Bonfield","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025031206132002300_CIT0040","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1074\/mcp.M800428-MCP200","article-title":"Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer","volume":"8","author":"Nibbe","year":"2009","journal-title":"Mol Cell Proteomics"},{"key":"2025031206132002300_CIT0041","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/art.40077","article-title":"Pathogenesis of diffuse alveolar hemorrhage in murine lupus","volume":"69","author":"Zhuang","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025031206132002300_CIT0042","doi-asserted-by":"publisher","first-page":"113000","DOI":"10.1016\/j.jim.2021.113000","article-title":"Interactions of human mesenchymal stromal cells with peripheral blood mononuclear cells in a Mitogenic proliferation assay","volume":"492","author":"Herzig","year":"2021","journal-title":"J Immunol Methods"},{"key":"2025031206132002300_CIT0043","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/cells8121659","article-title":"The phenotype and secretory activity of adipose-derived mesenchymal stem cells (ASCs) of patients with rheumatic diseases","volume":"8","author":"Kuca-Warnawin","year":"2019","journal-title":"Cells"},{"key":"2025031206132002300_CIT0044","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"2025031206132002300_CIT0045","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"key":"2025031206132002300_CIT0046","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jcyt.2018.02.003","article-title":"Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells","volume":"20","author":"Guan","year":"2018","journal-title":"Cytotherapy"},{"key":"2025031206132002300_CIT0047","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1089\/hum.2010.136","article-title":"\u201cMesenchymal\u201d stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease","volume":"21","author":"Bianco","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2025031206132002300_CIT0048","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.biomaterials.2009.11.064","article-title":"The recruitment of two consecutive and different waves of host stem\/progenitor cells during the development of tissue-engineered bone in a murine model","volume":"31","author":"Tasso","year":"2010","journal-title":"Biomaterials"},{"key":"2025031206132002300_CIT0049","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.placenta.2009.12.006","article-title":"Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche","volume":"31","author":"Castrechini","year":"2010","journal-title":"Placenta"},{"key":"2025031206132002300_CIT0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/0470857897.ch8","article-title":"The KEGG database","volume":"247","author":"Kanehisa","year":"2002","journal-title":"Novartis Found Symp"},{"key":"2025031206132002300_CIT0051","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"2025031206132002300_CIT0052","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"2025031206132002300_CIT0053","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"2025031206132002300_CIT0054","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"2025031206132002300_CIT0055","article-title":"HXB-319, a new generation Mesenchymal Stromal Cell (MSC) therapy, alleviates neutrophilic inflammation, and end-organ damage in pulmonary renal syndromes by inducing FoxP3+ Tregs, and by promoting TNF\u03b1-stimulated gene-6 (TSG-6) over expression","author":"Bukulmez","year":"2023"},{"key":"2025031206132002300_CIT0056","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/stem.2509","article-title":"Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression","volume":"35","author":"Davies","year":"2017","journal-title":"Stem Cells"},{"key":"2025031206132002300_CIT0057","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/scrt68","article-title":"Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6","volume":"2","author":"Danchuk","year":"2011","journal-title":"Stem Cell Res Ther"},{"key":"2025031206132002300_CIT0058","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11596-017-1763-3","article-title":"Bone marrow mesenchymal stem cells ameliorate lung injury through anti-inflammatory and antibacterial effect in COPD mice","volume":"37","author":"Liu","year":"2017","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2025031206132002300_CIT0059","doi-asserted-by":"publisher","first-page":"126651","DOI":"10.1016\/j.ijbiomac.2023.126651","article-title":"Anti-inflammatory protein TSG-6 secreted by BMSCs attenuates silica-induced acute pulmonary inflammation by inhibiting NLRP3 inflammasome signaling in macrophages","volume":"253","author":"Su","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"2025031206132002300_CIT0060","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0165-2478(03)00101-9","article-title":"Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine\/CX3CL1","volume":"89","author":"Guo","year":"2003","journal-title":"Immunol Lett"},{"key":"2025031206132002300_CIT0061","doi-asserted-by":"publisher","first-page":"e10088","DOI":"10.1371\/journal.pone.0010088","article-title":"A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype","volume":"5","author":"Waterman","year":"2010","journal-title":"PLoS One"},{"key":"2025031206132002300_CIT0062","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cytogfr.2019.05.006","article-title":"Mesenchymal stem cells immunomodulation: the road to IFN-gamma licensing and the path ahead","volume":"47","author":"Carvalho","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025031206132002300_CIT0063","doi-asserted-by":"publisher","first-page":"708950","DOI":"10.3389\/fimmu.2021.708950","article-title":"Dichotomic potency of IFNgamma licensed allogeneic mesenchymal stromal cells in animal models of acute radiation syndrome and graft versus host disease","volume":"12","author":"Chinnadurai","year":"2021","journal-title":"Front Immunol"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxae078\/61099292\/sxae078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/43\/2\/sxae078\/61099292\/sxae078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/43\/2\/sxae078\/61099292\/sxae078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T06:13:41Z","timestamp":1741760021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/doi\/10.1093\/stmcls\/sxae078\/7904576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,12]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxae078","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,19]]},"article-number":"sxae078"}}